Placebo + LY3041658
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hidradenitis Suppurativa
Conditions
Hidradenitis Suppurativa
Trial Timeline
Aug 26, 2020 → Oct 13, 2022
NCT ID
NCT04493502About Placebo + LY3041658
Placebo + LY3041658 is a phase 2 stage product being developed by Eli Lilly for Hidradenitis Suppurativa. The current trial status is completed. This product is registered under clinical trial identifier NCT04493502. Target conditions include Hidradenitis Suppurativa.
What happened to similar drugs?
1 of 20 similar drugs in Hidradenitis Suppurativa were approved
Approved (1) Terminated (0) Active (19)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04493502 | Phase 2 | Completed |
Competing Products
20 competing products in Hidradenitis Suppurativa
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 41 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 38 |
| Sonelokimab (M1095) + Adalimumab | MoonLake Immunotherapeutics | Phase 2 | 29 |
| Eltrekibart + Placebo | Eli Lilly | Phase 2 | 39 |
| Placebo + Adalimumab | AbbVie | Approved | 43 |
| Lutikizumab + Placebo | AbbVie | Phase 3 | 47 |
| Adalimumab | AbbVie | Pre-clinical | 26 |
| Upadacitinib + Placebo | AbbVie | Phase 3 | 47 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Lutikizumab | AbbVie | Phase 2 | 42 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Lutikizumab + Placebo | AbbVie | Phase 2 | 39 |
| Risankizumab + Placebo for risankizumab | AbbVie | Phase 2 | 35 |
| adalimumab | AbbVie | Phase 3 | 40 |
| adalimumab + placebo | AbbVie | Phase 3 | 40 |
| Upadacitinib + Placebo | AbbVie | Phase 2 | 35 |
| MEDI8968 + Saline | AstraZeneca | Phase 2 | 27 |
| Anifrolumab | AstraZeneca | Phase 2 | 39 |